Plain-English translation of NCT03362164 on ClinicalTrials.gov ↗ · Source last updated · Translation generated · How we translate trials
This is a long-term research study that has been observing patients with Fabry disease since 2001. Researchers want to learn more about how Fabry disease affects the heart, who is at risk for life-threatening heart rhythms, and what signs doctors should watch for. By studying a large group of patients over time, they hope to better predict and prevent serious heart complications.
Fabry disease is a rare genetic condition that often leads to serious heart problems, and people with Fabry disease have historically not lived past age 50. This study exists to help doctors identify which patients are most at risk for sudden cardiac death and heart failure so they can provide better care and potentially save lives.
You likely qualify if…
You likely don't qualify if…
You would be followed as part of this study at the Fabry Center in Würzburg, Germany. Researchers will monitor your heart health through regular visits and tests over time — some patients have been in this study since 2001. This is an observational study, meaning you are not taking a new medication; instead, doctors are carefully tracking your condition and outcomes to learn more about heart involvement in Fabry disease.
AI-generated summary from trial data · Jun 2, 2026 · Not medical advice
Germany
Competence Network Heart Failure, Academisch Medisch Centrum - Universiteit van Amsterdam (AMC-UvA)
Enrollment target
~650 participants
Started
January 2001
Primary completion
March 2032
Age range
18 Years and older
Last updated on clinicaltrials.gov in July 2022.
Reach out to the team running this trial. Response times vary — some teams are faster than others.
Central contact
Peter Nordbeck, MD, PhD
Wuerzburg University Hospital
Tell us you're interested and we'll help connect you with the research team. We'll walk you through what to expect first — no email needed to get started.